menu
    • menu
    [{"orgOrder":0,"company":"Navitas Inc","sponsor":"Shenyang Sunshine Pharmaceutical Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase IV","graph3":"Navitas Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navitas Inc \/ Navitas Inc","highestDevelopmentStatusID":"11","companyTruncated":"Navitas Inc \/ Navitas Inc"},{"orgOrder":0,"company":"Navitas Inc","sponsor":"Shenyang Sunshine Pharmaceutical Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase IV","graph3":"Navitas Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navitas Inc \/ Navitas Inc","highestDevelopmentStatusID":"11","companyTruncated":"Navitas Inc \/ Navitas Inc"},{"orgOrder":0,"company":"Navitas Inc","sponsor":"IndiPharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cicletanine","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Navitas Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navitas Inc \/ IndiPharm","highestDevelopmentStatusID":"7","companyTruncated":"Navitas Inc \/ IndiPharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Navitas Inc

    Menu

    Navitas Inc

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Navitas Inc

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Navitas Inc

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Recipient : Shenyang Sunshine Pharmaceutical Co Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)

                            Details : Epoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Renal.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 27, 2016

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Recipient : Shenyang Sunshine Pharmaceutical Co Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Navitas Inc

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Navitas Inc

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cicletanine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : IndiPharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium

                            Details : Cicletanine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2016

                            Lead Product(s) : Cicletanine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : IndiPharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Navitas Inc

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Navitas Inc

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Recipient : Shenyang Sunshine Pharmaceutical Co Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)

                            Details : Epoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia, Renal.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 14, 2015

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Recipient : Shenyang Sunshine Pharmaceutical Co Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth